| Literature DB >> 19592480 |
Sílvia Helena Cestari1, Jairo Kennup Bastos, Luiz Claudio Di Stasi.
Abstract
Baccharis dracunculifolia DC (Asteraceae) is a Brazilian medicinal plant popularly used for its antiulcer and anti-inflammatory properties. This plant is the main botanical source of Brazilian green propolis, a natural product incorporated into food and beverages to improve health. The present study aimed to investigate the chemical profile and intestinal anti-inflammatory activity of B. dracunculifolia extract on experimental ulcerative colitis induced by trinitrobenzenosulfonic acid (TNBS). Colonic damage was evaluated macroscopically and biochemically through its evaluation of glutathione content and its myeloperoxidase (MPO) and alkaline phosphatase activities. Additional in vitro experiments were performed in order to test the antioxidant activity by inhibition of induced lipid peroxidation in the rat brain membrane. Phytochemical analysis was performed by HPLC using authentic standards. The administration of plant extract (5 and 50 mg kg(-1)) significantly attenuated the colonic damage induced by TNBS as evidenced both macroscopically and biochemically. This beneficial effect can be associated with an improvement in the colonic oxidative status, since plant extract prevented glutathione depletion, inhibited lipid peroxidation and reduced MPO activity. Caffeic acid, p-coumaric acid, aromadendrin-4-O-methyl ether, 3-prenyl-p-coumaric acid, 3,5-diprenyl-p-coumaric acid and baccharin were detected in the plant extract.Entities:
Year: 2011 PMID: 19592480 PMCID: PMC3136549 DOI: 10.1093/ecam/nep081
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Criteria for assessment of macroscopic colonic damage
| Score | Criteria |
|---|---|
| 0 | No damage |
| 1 | Hyperemia, no ulcers |
| 2 | Linear ulcer with no significant inflammation |
| 3 | Linear ulcer with inflammation at one site |
| 4 | Two or more sites of ulceration/inflammation |
| 5 | Two or more major sites of ulceration and inflammation or one site of ulceration/inflammation extending >1 cm along the length of the colon |
| 6–10 | If damage covers >2 cm along the length of the colon, the score is increased by 1 for each additional centimeter of involvement |
Effects of B. dracunculifolia extract (5–200 mg kg−1) and sulfasalazine (25 mg kg−1) on damage score, changes in colonic weight/length, diarrhea and adherence incidence in TNBS acute colitis
| Group | Damage scorea (0–10) | Colonic weight/lengthb (mg cm−1) | Diarrhoea (%) | Adherence (%) |
|---|---|---|---|---|
| Non-colitic | 0*** | 82.30 ± 3.86** | 0 | 0 |
| TNBS-control | 8.5 (7–9) | 146.99 ± 8.78 | 80.0 | 50.0 |
|
| ||||
| 5 mg kg−1 | 6.0 (5–8)* | 127.44 ± 8.06 | 50.0 | 50.0 |
| 10 mg kg−1 | 7.5 (6–8) | 127.82 ± 3.94 | 50.0 | 66.7 |
| 25 mg kg−1 | 7.5 (5–10) | 135.28 ± 6.33 | 66.7 | 66.7 |
| 50 mg kg−1 | 6.5 (5–8)* | 139.10 ± 9.05 | 33.3* | 0* |
| 100 mg kg−1 | 6.5 (4–8) | 131.53 ± 7.34 | 83.3 | 33.3 |
| 200 mg kg−1 | 7.0 (4–8) | 134.62 ± 9.11 | 50.0 | 33.3 |
| Sulfasalazine | 6.0 (2–8)** | 133.58 ± 12.38 | 16.7 | 50.0 |
aScore data are expressed as median (range).
bColonic weight data are expressed as mean ± SEM.
*P < .05; **P < .01; ***P < .001 versus TNBS control group.
Effects of B. dracunculifolia extract (5–200 mg kg−1) and sulfasalazine (25 mg kg−1) on GSH content, MPO activity and AP activity in TNBS acute colitis
| Group | GSH content (nmol g−1 tissue) | MPO activity (U g−1 tissue) | AP activity (mU mg−1 protein) |
|---|---|---|---|
| Non-colitic | 1357.5 ± 86.5** | 84.2 ± 8.7** | 6.24 ± 0.36* |
| TNBS control | 759.6 ± 31.9 | 684.2 ± 62.8 | 12.62 ± 1.72 |
|
| |||
| 5 mg kg−1 | 967.3 ± 55.0* | 324.9 ± 89.9** | 10.53 ± 1.21 |
| 10 mg kg−1 | 850.3 ± 27.8 | 532.8 ± 96.3 | 14.58 ± 1.36 |
| 25 mg kg−1 | 878.5 ± 82.7 | 576.4 ± 79.8 | 14.27 ± 2.02 |
| 50 mg kg−1 | 809.4 ± 55.0 | 216.9 ± 31.6** | 6.16 ± 0.63* |
| 100 mg/kg−1 | 873.8 ± 25.8 | 245.8 ± 39.9** | 7.45 ± 0.93 |
| 200 mg kg−1 | 930.9 ± 113.8 | 380.1 ± 84.4* | 9.54 ± 1.76 |
| Sulfasalazine | 1006.2 ± 87.0* | 419.8 ± 80.1* | 9.02 ± 1.56 |
Data are expressed as mean ± SEM. *P < .05, **P < .01 versus TNBS control group.
Effects of B. dracunculifolia extract (5 and 50 mg kg−1) and sulfasalazine (25 mg kg−1) on damage score, changes in colonic weight/length, diarrhea and adherence incidence in TNBS chronic colitis with relapse
| Group | Damage scorea (0–10) | Colonic weight/lenghtb (mg cm−1) | Diarrhoea (%) | Adherence (%) |
|---|---|---|---|---|
| 1 week | ||||
| Non-colitic | 0*** | 100.57 ± 8.03** | 0* | |
| TNBS-control | 8.0 (7–9) | 276.10 ± 31.17 | 83.3 | |
|
| 2.0 (0–4)* | 140.53 ± 8.61** | 0* | |
|
| 1.0 (0–5)* | 171.00 ± 22.91** | 33.3 | |
| Sulfasalazine 25 mg kg−1 | 3.5 (2–7) | 143.25 ± 20.56** | 0 | |
| 2 week | ||||
| Non-colitic | 0*** | 87.16 ± 4.32** | 0 | |
| TNBS-control | 2.5 (2–3) | 185.40 ± 22.21 | 16.7 | |
|
| 3.0 (0–4) | 117.50 ± 6.45** | 0 | |
|
| 4.0 (2–5) | 141.90 ± 12.02 | 33.3 | |
| Sulfasalazine 25 mg kg−1 | 4.0 (1–6) | 137.95 ± 10.73 | 0 |
aScore data are expressed as median (range).
bColonic weight data are expressed as mean ± SEM.
*P < .05, **P < .01, ***P < .001 versus TNBS control group.
Effects of B. dracunculifolia extract (5 and 50 mg kg−1) and sulfasalazine (25 mg kg−1) on GSH content, MPO activity and AP activity in TNBS chronic colitis with relapse
| Group | GSH content (nmol g−1 tissue) | MPO activity (U g−1 tissue) | AP activity (mU mg−1 protein) |
|---|---|---|---|
| 1 week | |||
| Non-colitic | 2357.6 ± 311.3* | 127.6 ± 14.5** | 4.20 ± 0.36** |
| TNBS control | 1590.1 ± 53.6 | 1045.2 ± 231.2 | 19.15 ± 4.38 |
|
| 2386.1 ± 177.1* | 221.1 ± 59.2* | 7.93 ± 1.13** |
|
| 2218.6 ± 97.4* | 167.6 ± 12.7* | 8.31 ± 1.51** |
| Sulfasalazine 25 mg kg−1 | 1992.2 ± 254.2 | 951.0 ± 328.0 | 7.45 ± 0.92** |
| 2 week | |||
| Non-colitic | 2233.9 ± 192.5 | 115.9 ± 12.9 | 5.79 ± 0.70** |
| TNBS control | 1881.3 ± 146.8 | 220.6 ± 42.9 | 13.31 ± 1.65 |
|
| 2228.3 ± 132.7* | 167.5 ± 31.7 | 8.39 ± 1.07* |
|
| 2538.2 ± 132.8** | 178.5 ± 34.6 | 8.78 ± 1.13* |
| Sulfasalazine 25 mg kg−1 | 1776.6 ± 63.5 | 262.4 ± 59.4 | 11.20 ± 1.29 |
Data are expressed as mean ± SEM.
*P < .05, **P < .01 versus TNBS control group.
Figure 1Structures of chemical constituents in the ethyl acetate extract of B. dracunculifolia. (1) caffeic acid; (2) p-coumaric acid; (3) aromadendrin-4-O-methyl ether; (4) 3-prenyl-p-coumaric acid (drupanin); (5) 3,5-diprenyl p-coumaric acid (artepillin C); (6) baccharin.
Figure 2HPLC profile of B. dracunculifolia: (1) caffeic acid; (2) p-coumaric acid; (3) aromadendrin-4-O-methyl ether; (4) 3-prenyl-p-coumaric acid (drupanin); (5) 3,5-diprenyl p-coumaric acid (artepillin C); (6) baccharin.
Figure 3Main effects of the B. dracunculifolia on the inflammatory intestinal process induced by TNBS in rats. Black lines indicate inhibition and black arrows indicate counteraction of depletion induced by the inflammatory process.